Matthew Wheatley is a partner in the Antitrust Department who counsels clients on a wide array of competition issues arising in complex transactions and government enforcement actions. He has extensive experience advising on the premerger notification process under the Hart-Scott-Rodino (HSR) Act and overseeing antitrust aspects of multibillion-dollar deals in the healthcare and pharmaceutical industries. Matt has been recognized by The Legal 500 in the Civil Litigation/Class Actions: Defense category (2022) and the Antitrust: Merger Control category (2020), and was named "outstanding" in Washington, D.C. by Global Competition Review (2022).
Matthew is widely published and his notable contributions include:
- “An Antitrust Roadmap for Private Equity Investment,” Antitrust by the American Bar Association, August 2020
- “Merger Control 2020, USA Chapter,” Global Legal Insights, July 2020
